Robert Saltzmann, MD
Ophthalmology · Belmont, NCNPI 1548463433
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 155 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Alcon at 34.8% of the total.
Across 155 payments — averaging $43.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- AbbVie$2K
- Aerie Pharmaceuticals, Inc.$651
- NEW World Medical,inc.$450
- Ivantis, Inc$277
- Amgen$264
- plus $823 from 9 others
Across 78 payments — averaging $2839.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$222K
What the payments were for
- Food & beverage$6,66499%
- Gifts$901%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 36 | $2,348 |
| AbbVie(2 entities) | 63 | $1,941 |
| Aerie Pharmaceuticals, Inc. | 15 | $651 |
| NEW World Medical,inc. | 5 | $450 |
| Ivantis, Inc | 4 | $277 |
| Amgen(2 entities) | 4 | $264 |
| Sight Sciences, Inc. | 8 | $264 |
| Bausch & Lomb Americas Inc. | 5 | $194 |
| GSK | 1 | $95 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $83 |
| Sun Pharmaceutical Industries Inc. | 4 | $75 |
| Thea Pharma Inc. | 2 | $49 |
| Tarsus Pharmaceuticals, Inc. | 1 | $33 |
| Rayner Intraocular Lenses Limited | 1 | $16 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$667
- Rhopressa$465
- Rocklatan$465
- XEN GLAUCOMA TREATMENT SYSTEM$335
- Ahmed Glaucoma Valve$287
- Kahook Dual Blade$287
- LenSx$263
- Clareon$248
- TEPEZZA$246
- Clearpath$168
- Streamline$168
- Via360$168
- AcrySof IQ VIVITY IOL$148
- NGENUITY$138
- Luxor$138
- VUITY$132
- PanOptix$128
- LUMIGAN$125
- XEN$125
- DURYSTA$125
How this compares
$6,754 in reported general payments places this provider in the 85th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 242 | $134,932 |
| CombiganBrimonidine Tartrate/Timolol | 222 | $95,306 |
| RestasisCyclosporine | 56 | $68,945 |
| RocklatanNetarsudil Mesylat/Latanoprost | 67 | $40,670 |
| Latanoprost | 2,959 | $32,067 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 162 | $26,937 |
| Travoprost | 144 | $25,770 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 79 | $24,001 |
| Prednisolone Acetate | 341 | $20,297 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 846 | $16,167 |
| Alphagan PBrimonidine Tartrate | 38 | $14,879 |
| VyzultaLatanoprostene Bunod | 39 | $14,479 |
| Brimonidine Tartrate | 423 | $12,590 |
| ProlensaBromfenac Sodium | 28 | $9,803 |
| IyuzehLatanoprost/Pf | 29 | $8,481 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $1,941 | $314,062558 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $651 | $40,67067 claims |
| AlconSimbrinza | $2,348 | $24,00179 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $194 | $14,47939 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $83 | $12,27255 claims |
| Thea Pharma Inc.Iyuzeh | $49 | $8,48129 claims |
| NovartisIlevro | $13 | $4,71113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 588 ophthalmology providers in North Carolina.
Other ophthalmology in Belmont
- Preeya GuptaRaleigh$1.8M
- Julie WoodwardDurham$1M
- Rajiv ShahWinston Salem$909K
- Lejla VajzovicDurham$681K
- Karl StonecipherGreensboro$653K
- Terry KimDurham$605K
- Keith WalterWinston Salem$397K
- Leon HerndonDurham$230K
- Thomas MundorfCharlotte$220K
- Glenn JaffeDurham$218K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.